Document Detail


Recent developments on immunotherapy for brain cancer.
MedLine Citation:
PMID:  22533851     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Brain tumors are a unique class of cancers since they are anatomically shielded from normal immunosurveillance by the blood-brain barrier, lack a normal lymphatic drainage system and reside in a potently immunosuppressive environment. Of the primary brain cancers, glioblastoma multiforme (GBM) is the most common and aggressive in adults. Although treatment options include surgery, radiation and chemotherapy, the average lifespan of GBM patients remains at only 14.6 months post-diagnosis.
AREAS COVERED: A review of key cellular and molecular immune system mediators in the context of brain tumors including TGF-β, cytotoxic T cells, Tregs, CTLA-4, PD-1 and IDO is discussed. In addition, prognostic factors, currently utilized immunotherapeutic strategies, ongoing clinical trials and a discussion of new or potential immunotherapies for brain tumor patients are considered.
EXPERT OPINION: Current drugs that improve the quality of life and overall survival in patients with brain tumors, especially for GBM, are poorly effective. This disease requires a reanalysis of currently accepted treatment strategies, as well as newly designed approaches. Here, we review the fundamental aspects of immunosuppression in brain tumors, new and promising immunotherapeutic drugs as well as combinatorial strategies that focus on the simultaneous inhibition of immunosuppressive hubs, both in immune and brain tumor cells, which is critical to consider for achieving future success for the treatment of this devastating disease.
Authors:
Derek A Wainwright; Pragati Nigam; Bart Thaci; Mahua Dey; Maciej S Lesniak
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2012-04-25
Journal Detail:
Title:  Expert opinion on emerging drugs     Volume:  17     ISSN:  1744-7623     ISO Abbreviation:  Expert Opin Emerg Drugs     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-28     Completed Date:  2012-10-17     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101135662     Medline TA:  Expert Opin Emerg Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  181-202     Citation Subset:  IM    
Affiliation:
The University of Chicago, Chicago, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Brain Neoplasms / immunology*,  therapy*
Clinical Trials as Topic
Drug Evaluation, Preclinical
Humans
Immunotherapy / methods*
Randomized Controlled Trials as Topic
Grant Support
ID/Acronym/Agency:
F32 NS073366/NS/NINDS NIH HHS; R01 CA122930/CA/NCI NIH HHS; R01 CA138587/CA/NCI NIH HHS; R01 CA138587-05/CA/NCI NIH HHS; U01 NS069997/NS/NINDS NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis and Biological Evaluation of Fatty Acyl Ester Derivatives of (-)-2',3'-Dideoxy-3'-Thiacyti...
Next Document:  Harmful drinking and talking about alcohol in primary care: New Zealand population survey findings.